Among over 1.1 million patients with mild cognitive impairment or dementia, only 0.2% received FDA-approved antiamyloid monoclonal antibodies (aducanumab, lecanemab, donanemab) from 2021 to 2024.
Younger, non-Hispanic White patients with fewer comorbidities and lower socioeconomic vulnerability had higher odds of receiving these novel treatments.
Higher Elixhauser comorbidity score was associated with poorer initial adherence to antiamyloid medications, while age, sex, race/ethnicity, and neighborhood vulnerability did not significantly impact early adherence.
These findings expose potential disparities in access to emerging Alzheimer’s therapies that could hinder equitable dementia care advancement.
